根据美国食品药品管理局（FDA）发布的安全警告，患有无肝硬化的原发性胆汁性胆管炎（PBC）的患者使用Ocaliva® （奥贝胆酸）治疗时报告了严重的肝损伤。 Ocaliva 是一种法呢醇 X 受体激动剂，于 2016 年获得加速批准用于治疗 ...

Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary supplements.

It also improves bile acid clearance and modulates transporters in the liver and kidney, enhancing the elimination of both bile acids and toxic drugs. Furthermore, UDCA protects cholangiocytes by ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the ...

Degree of benefit with UDCA is uncertain. Aim: To Look at Mode of diagnosis for CFALD and Effectiveness & safety of UDCA in our unit. Methods: Retrospective review on all patients currently ...

Analysts have suggested that the US market for drugs to treat UDCA-refractory PBC could be worth $1.5 billion or more per year. Gilead acquired Livdelzi – an oral PPAR delta agonist – as the ...

The ground-breaking study, led by researchers at the University of Sheffield in partnership with Sheffield Teaching Hospitals NHS Foundation Trust, is assessing the safety and tolerability of the ...

Discover all the brand names or Trade names of generic drug called Ursodeoxycholic Acid. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking ...

Two hits to come out of our drug screening programmes are: Ursodeoxycholic acid, (UDCA), a repurposed drug for Parkinson’s now entering phase 3 clinical trials for neuroprotection in patients. M102, a ...

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...